B-Cell Non-Hodgkin’s Lymphoma Epidemiology Analysis and Forecast to 2033

All the vital news, analysis, and commentary curated by our industry experts.

$9995

Buy Report

Published: March 31, 2025 Report Code: GDHCER335-25-ST

Report Overview
Key Players
Table of Contents
Table
Figures

Non-Hodgkin’s lymphoma (NHL) represents a group of cancers that develop in the lymphatic system. Individuals with NHL experience uncontrolled malignant white blood cells, rendering the immune system incapable of effectively fighting off infections. Among all malignant lymphomas, the 90% are composed of NHL, making it among the most prevalent hematological adult cancers (Ekströ Smedby et al., 2008).

NHL is segmented by its histology into B-cell, T-cell, and natural killer lymphocyte lymphoma, with B-cell lymphoma constituting 80─85% of the three subtypes. B-cell lymphoma is distinguished into further subtypes, each of which exhibits its own unique pathology and behavior. Among them, diffuse large B-cell lymphoma (DLBCL) is the most prevalent at 33-51% of cases, followed by follicular lymphoma (FL) at 18-51% of cases. Other common B-cell NHLs include marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL), which compose 10-20% and 4-5% of cases, respectively. Each subtype is characterized by specific segmentations, including the distinction of DLBCL into germinal (GCB) and non-germinal center B-cell (non-GCB), as well as the subclassification of FL by histological features into grades 1,2, and 3 (Shustik et al., 2011; Singh et al., 2020).

Scope

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for B-cell NHL in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed incident and five-year prevalent cases of B-cell NHL. The diagnosed incident and five-year diagnosed prevalent cases of B-cell NHL are segmented by age (18 years and older), sex, and subtype (DLBCL, FL, MZL, and MCL). Furthermore, diagnosed incident and five-year diagnosed prevalent cases of each subtype are segmented by relevant subtype-specific clinical features, including the distinction between GCB and non-GCB DLBCL, FL grade, bulky and non-bulky disease among stage II FL and MCL cases, and Ann Arbor staging (stages I─IV) for all four subtypes. Finally, five-year diagnosed prevalent cases of all subtypes are segmented into cases that have relapsed and those that are in remission or active.

Reasons to Buy

The B-Cell Non-Hodgkin's Lymphoma Epidemiology series will allow you to –

Develop business strategies by understanding the trends shaping and driving the global B-cell NHL markets.

Quantify patient populations in the global B-cell NHL markets to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for B-cell NHL therapeutics in each of the markets covered.

Understand magnitude of the B-cell NHL population by age, sex, histology, and subtype-specific stage at diagnosis.

About GlobalData

List of Contents

List of Tables

List of Figures

1 B-Cell Non-Hodgkin’s Lymphoma: Executive Summary

1.1 Catalyst

1.2 Related reports

1.3 Upcoming reports

2 Epidemiology

2.1 Disease background

2.2 Risk factors and comorbidities

2.3 Global and historical trends

2.4 7MM forecast methodology

2.4.1 Sources

2.4.2 Forecast assumptions and methods

2.4.3 Forecast assumptions and methods: diagnosed incident cases of B-cell NHL – 7MM

2.4.4 Forecast assumptions and methods: diagnosed incident cases of diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma

2.4.5 Forecast assumptions and methods: diagnosed incident cases of B-cell NHL by stage

2.4.6 Forecast assumptions and methods: five-year diagnosed prevalent cases of B-cell NHL

2.4.7 Forecast assumptions and methods: five-year diagnosed prevalent cases of diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma

2.4.8 Forecast assumptions and methods: five-year diagnosed prevalent cases of B-cell NHL by stage

2.4.9 Forecast assumptions and methods: five-year diagnosed prevalent cases of diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma that progress from local and regional to advanced stages

2.5 Epidemiological forecast for B-cell NHL (2023-33)

2.5.1 Diagnosed incident cases of B-cell NHL

2.5.2 Age-specific diagnosed incident cases of B-cell NHL

2.5.3 Sex-specific diagnosed incident cases of B-cell NHL

2.5.4 Diagnosed incident cases of B-cell NHL by subtype

2.5.5 Diagnosed incident cases of diffuse large B-cell lymphoma by Ann Arbor staging

2.5.6 Diagnosed incident cases of follicular lymphoma by Ann Arbor staging

2.5.7 Diagnosed incident cases of marginal zone lymphoma by Ann Arbor staging

2.5.8 Diagnosed incident cases of mantle cell lymphoma by Ann Arbor staging

2.5.9 Five-year diagnosed prevalent cases of B-cell NHL

2.5.10 Age-specific five-year diagnosed prevalent cases of B-cell NHL

2.5.11 Sex-specific five-year diagnosed prevalent cases of B-cell NHL

2.5.12 Five-year diagnosed prevalent cases of B-cell NHL by subtype

2.5.13 Five-year diagnosed prevalent cases of diffuse large B-cell lymphoma by Ann Arbor staging

2.5.14 Five-year diagnosed prevalent cases of follicular lymphoma by Ann Arbor staging

2.5.15 Five-year diagnosed prevalent cases of marginal zone lymphoma by Ann Arbor staging

2.5.16 Five-year diagnosed prevalent cases of mantle cell lymphoma by Ann Arbor staging

2.6 Discussion

2.6.1 Epidemiological forecast insight

2.6.2 Limitations of the analysis

2.6.3 Strengths of the analysis

3 Appendix

3.1 Bibliography

3.2 Primary market research – prescriber survey

3.3 About the Authors

3.3.1 Epidemiologist

3.3.2 Reviewers

3.3.3 Vice President of Disease Analysis and Intelligence

3.3.4 Global Head and EVP of Healthcare Operations and Strategy

Table

Table 1: Summary of newly added data types

Table 2: Summary of updated data types

Table 3: B-cell NHL Lugano cancer stages

Table 4: B-cell NHL Ann Arbor cancer stages

Table 5: Risk factors and comorbidities for B-cell NHL

Table 6: High-prescribing physicians surveyed, by country

Figures

Figure 1: 7MM, diagnosed incident cases of B-cell NHL, both sexes, N, ages ≥18 years, 2023 and 2033

Figure 2: 7MM, five-year diagnosed prevalent cases of B-cell NHL, both sexes, N, ages ≥18 years, 2023 and 2033

Figure 3: 7MM, diagnosed incidence of B-cell NHL, both sexes, cases per 100,000 population, ages ≥18 years, 2023─33

Figure 4: 7MM, five-year diagnosed prevalence of B-cell NHL, both sexes, %, ages ≥18 years, 2023─33

Figure 5: 7MM, sources used to forecast the diagnosed incident cases of B-cell NHL

Figure 6: 7MM, sources used to forecast the diagnosed and five-year diagnosed prevalent cases of B-cell NHL

Figure 7: 7MM, sources used to forecast the diagnosed incident cases of B-cell NHL by histological subtype

Figure 8: 7MM, sources used to forecast the five-year diagnosed prevalent cases of B-cell NHL by histological subtype

Figure 9: 7MM, sources used to forecast the diagnosed incident cases of B-cell NHL by stage

Figure 10: 7MM, sources used to forecast the five-year diagnosed prevalent cases of B-cell NHL by stage

Figure 11: 7MM, diagnosed incident cases of B-cell NHL, N, both sexes, ages ≥18 years, 2023

Figure 12: 7MM, diagnosed incident cases of B-cell NHL by age, N, both sexes, 2023

Figure 13: 7MM, diagnosed incident cases of B-cell NHL by sex, N, ages ≥18 years, 2023

Figure 14: 7MM, diagnosed incident cases of B-cell NHL by subtype, N, both sexes, ages ≥18 years, 2023

Figure 15: 7MM, diagnosed incident cases of DLBCL by Ann Arbor staging, N, both sexes, ages ≥18 years, 2023

Figure 16: 7MM, diagnosed incident cases of FL by Ann Arbor staging, N, both sexes, ages ≥18 years, 2023

Figure 17: 7MM, diagnosed incident cases of MZL by Ann Arbor staging, N, both sexes, ages ≥18 years, 2023

Figure 18: 7MM, diagnosed incident cases of MCL by Ann Arbor staging, N, both sexes, ages ≥18 years, 2023

Figure 19: 7MM, five-year diagnosed prevalent cases of B-cell NHL, N, both sexes, ages ≥18 years, 2023

Figure 20: 7MM, five-year diagnosed cases of B-cell NHL by age, N, both sexes, 2023

Figure 21: 7MM, five-year diagnosed prevalent cases of B-cell NHL by sex, N, ages ≥18 years, 2023

Figure 22: 7MM, five-year diagnosed prevalent cases of B-cell NHL by subtype, N, both sexes, ages ≥18 years, 2023

Figure 23: 7MM, five-year diagnosed prevalent cases of DLBCL by Ann Arbor staging, N, both sexes, ages ≥18 years, 2023

Figure 24: 7MM, five-year diagnosed prevalent cases of FL by Ann Arbor staging, N, both sexes, ages ≥18 years, 2023

Figure 25: 7MM, five-year diagnosed prevalent cases of MZL by Ann Arbor staging, N, both sexes, ages ≥18 years, 2023

Figure 26: 7MM, five-year diagnosed prevalent cases of MCL by Ann Arbor staging, N, both sexes, ages ≥18 years, 2023

B-Cell Non-Hodgkin’s Lymphoma Epidemiology Analysis and Forecast to 2033 standard reports

Currency USD

Single User

$9,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more B-Cell Non-Hodgkin Lymphoma reports

Pharmaceuticals

New

Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…

Pharmaceuticals

New

Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035

Pharmaceuticals

New

Overweight and Obesity: Epidemiology Report and Forecast to 2035

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at B-Cell Non-Hodgkin’s Lymphoma Epidemiology Analysis and Forecast to 2033 in real time.

Access a live B-Cell Non-Hodgkin’s Lymphoma Epidemiology Analysis and Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

B-Cell Non-Hodgkin’s Lymphoma Epidemiology Analysis and Forecast to 2033

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports